nodes	percent_of_prediction	percent_of_DWPC	metapath
Phentolamine—ADRA2C—attention deficit hyperactivity disorder	0.586	0.701	CbGaD
Phentolamine—ADRA2A—attention deficit hyperactivity disorder	0.25	0.299	CbGaD
Phentolamine—Naphazoline—ADRA2C—attention deficit hyperactivity disorder	0.00359	0.701	CrCbGaD
Phentolamine—Naphazoline—ADRA2A—attention deficit hyperactivity disorder	0.00153	0.299	CrCbGaD
Phentolamine—ADRA1D—forebrain—attention deficit hyperactivity disorder	0.00124	0.0816	CbGeAlD
Phentolamine—NISCH—midbrain—attention deficit hyperactivity disorder	0.000979	0.0646	CbGeAlD
Phentolamine—NISCH—cerebellum—attention deficit hyperactivity disorder	0.000757	0.05	CbGeAlD
Phentolamine—ADRA1A—forebrain—attention deficit hyperactivity disorder	0.000711	0.0469	CbGeAlD
Phentolamine—ADRA1B—nervous system—attention deficit hyperactivity disorder	0.000687	0.0453	CbGeAlD
Phentolamine—ADRA1D—nervous system—attention deficit hyperactivity disorder	0.000672	0.0443	CbGeAlD
Phentolamine—ADRA1B—central nervous system—attention deficit hyperactivity disorder	0.000661	0.0436	CbGeAlD
Phentolamine—ADRA1D—central nervous system—attention deficit hyperactivity disorder	0.000647	0.0427	CbGeAlD
Phentolamine—NISCH—brain—attention deficit hyperactivity disorder	0.000615	0.0406	CbGeAlD
Phentolamine—ADRA1A—cardiovascular system—attention deficit hyperactivity disorder	0.000601	0.0396	CbGeAlD
Phentolamine—SIGMAR1—midbrain—attention deficit hyperactivity disorder	0.000569	0.0376	CbGeAlD
Phentolamine—ADRA2A—forebrain—attention deficit hyperactivity disorder	0.00054	0.0356	CbGeAlD
Phentolamine—ADRA1B—brain—attention deficit hyperactivity disorder	0.000525	0.0346	CbGeAlD
Phentolamine—ADRA1D—brain—attention deficit hyperactivity disorder	0.000513	0.0339	CbGeAlD
Phentolamine—ADRA2C—midbrain—attention deficit hyperactivity disorder	0.000447	0.0295	CbGeAlD
Phentolamine—SIGMAR1—cerebellum—attention deficit hyperactivity disorder	0.00044	0.0291	CbGeAlD
Phentolamine—ADRA1A—nervous system—attention deficit hyperactivity disorder	0.000386	0.0255	CbGeAlD
Phentolamine—ADRA1A—central nervous system—attention deficit hyperactivity disorder	0.000371	0.0245	CbGeAlD
Phentolamine—ADRA2C—nervous system—attention deficit hyperactivity disorder	0.000368	0.0243	CbGeAlD
Phentolamine—ADRA1A—cerebellum—attention deficit hyperactivity disorder	0.000363	0.024	CbGeAlD
Phentolamine—SIGMAR1—brain—attention deficit hyperactivity disorder	0.000358	0.0236	CbGeAlD
Phentolamine—ADRA2A—midbrain—attention deficit hyperactivity disorder	0.000357	0.0235	CbGeAlD
Phentolamine—ADRA2C—central nervous system—attention deficit hyperactivity disorder	0.000354	0.0234	CbGeAlD
Phentolamine—ADRA2C—cerebellum—attention deficit hyperactivity disorder	0.000346	0.0228	CbGeAlD
Phentolamine—ADRA1A—brain—attention deficit hyperactivity disorder	0.000295	0.0195	CbGeAlD
Phentolamine—ADRA2A—nervous system—attention deficit hyperactivity disorder	0.000293	0.0194	CbGeAlD
Phentolamine—ADRA2A—central nervous system—attention deficit hyperactivity disorder	0.000282	0.0186	CbGeAlD
Phentolamine—ADRA2C—brain—attention deficit hyperactivity disorder	0.000281	0.0185	CbGeAlD
Phentolamine—ADRA2A—cerebellum—attention deficit hyperactivity disorder	0.000276	0.0182	CbGeAlD
Phentolamine—ADRA2A—brain—attention deficit hyperactivity disorder	0.000224	0.0148	CbGeAlD
Phentolamine—ADRA1B—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	6.14e-05	0.000427	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	6.09e-05	0.000423	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	6.06e-05	0.000422	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	6.04e-05	0.00042	CbGpPWpGaD
Phentolamine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	5.96e-05	0.000415	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	5.95e-05	0.000414	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	5.94e-05	0.000413	CbGpPWpGaD
Phentolamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	5.93e-05	0.000413	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	5.87e-05	0.000408	CbGpPWpGaD
Phentolamine—ADRA2C—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	5.87e-05	0.000408	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	5.87e-05	0.000408	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	5.85e-05	0.000407	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	5.85e-05	0.000407	CbGpPWpGaD
Phentolamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	5.83e-05	0.000405	CbGpPWpGaD
Phentolamine—ADRA1B—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	5.77e-05	0.000402	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	5.77e-05	0.000402	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	5.71e-05	0.000397	CbGpPWpGaD
Phentolamine—ADRA2B—Hemostasis—ADRA2A—attention deficit hyperactivity disorder	5.69e-05	0.000396	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	5.69e-05	0.000395	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	5.6e-05	0.000389	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	5.59e-05	0.000389	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	5.47e-05	0.000381	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	5.47e-05	0.000381	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	5.47e-05	0.00038	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	5.45e-05	0.000379	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	5.45e-05	0.000379	CbGpPWpGaD
Phentolamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	5.38e-05	0.000374	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	5.38e-05	0.000374	CbGpPWpGaD
Phentolamine—ADRA2C—Hemostasis—ADRA2A—attention deficit hyperactivity disorder	5.31e-05	0.000369	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	5.28e-05	0.000367	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	5.19e-05	0.000361	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	5.19e-05	0.000361	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	5.15e-05	0.000358	CbGpPWpGaD
Phentolamine—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	5.13e-05	0.000357	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	5.13e-05	0.000357	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	5.11e-05	0.000356	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	5.08e-05	0.000354	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	5.07e-05	0.000353	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	5.07e-05	0.000353	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	5.03e-05	0.00035	CbGpPWpGaD
Phentolamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	5.03e-05	0.00035	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	4.97e-05	0.000346	CbGpPWpGaD
Phentolamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	4.95e-05	0.000344	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	4.91e-05	0.000341	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	4.78e-05	0.000332	CbGpPWpGaD
Phentolamine—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	4.77e-05	0.000331	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	4.77e-05	0.000331	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	4.73e-05	0.000329	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	4.71e-05	0.000328	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	4.67e-05	0.000325	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	4.65e-05	0.000323	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	4.62e-05	0.000321	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	4.54e-05	0.000316	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	4.5e-05	0.000313	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	4.47e-05	0.000311	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	4.44e-05	0.000309	CbGpPWpGaD
Phentolamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	4.39e-05	0.000306	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	4.34e-05	0.000302	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	4.27e-05	0.000297	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	4.27e-05	0.000297	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	4.22e-05	0.000293	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	4.18e-05	0.000291	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	4.15e-05	0.000289	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	4.1e-05	0.000285	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	4.08e-05	0.000284	CbGpPWpGaD
Phentolamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	4.08e-05	0.000284	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	4.06e-05	0.000283	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	4.06e-05	0.000282	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	4.05e-05	0.000282	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	3.99e-05	0.000278	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	3.98e-05	0.000277	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	3.98e-05	0.000277	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	3.94e-05	0.000274	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	3.93e-05	0.000273	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	3.93e-05	0.000273	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	3.91e-05	0.000272	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	3.88e-05	0.00027	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	3.83e-05	0.000266	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	3.8e-05	0.000264	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	3.79e-05	0.000264	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	3.79e-05	0.000264	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	3.77e-05	0.000263	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	3.77e-05	0.000262	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	3.73e-05	0.00026	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	3.69e-05	0.000256	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	3.68e-05	0.000256	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	3.67e-05	0.000255	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	3.66e-05	0.000255	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	3.66e-05	0.000254	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	3.61e-05	0.000251	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	3.6e-05	0.00025	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	3.59e-05	0.00025	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	3.57e-05	0.000248	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	3.55e-05	0.000247	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	3.53e-05	0.000245	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	3.53e-05	0.000245	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	3.52e-05	0.000245	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	3.49e-05	0.000243	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	3.47e-05	0.000241	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	3.44e-05	0.00024	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	3.44e-05	0.00024	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	3.43e-05	0.000238	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	3.42e-05	0.000238	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	3.39e-05	0.000236	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	3.37e-05	0.000235	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	3.36e-05	0.000234	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	3.36e-05	0.000234	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	3.36e-05	0.000234	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	3.35e-05	0.000233	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—ADRA2C—attention deficit hyperactivity disorder	3.33e-05	0.000232	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	3.33e-05	0.000231	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	3.32e-05	0.000231	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	3.32e-05	0.000231	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	3.32e-05	0.000231	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	3.31e-05	0.00023	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	3.31e-05	0.00023	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	3.3e-05	0.00023	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	3.29e-05	0.000229	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	3.26e-05	0.000227	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	3.26e-05	0.000227	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	3.24e-05	0.000225	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	3.24e-05	0.000225	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	3.22e-05	0.000224	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	3.2e-05	0.000223	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	3.2e-05	0.000223	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	3.15e-05	0.000219	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	3.11e-05	0.000216	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	3.1e-05	0.000216	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	3.09e-05	0.000215	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	3.08e-05	0.000214	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	3.08e-05	0.000214	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	3.05e-05	0.000212	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	3.05e-05	0.000212	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	3.04e-05	0.000211	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	3.01e-05	0.000209	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	3.01e-05	0.000209	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	3e-05	0.000209	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	3e-05	0.000209	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	3e-05	0.000208	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	2.99e-05	0.000208	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	2.96e-05	0.000206	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	2.94e-05	0.000204	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	2.93e-05	0.000204	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	2.9e-05	0.000202	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	2.88e-05	0.0002	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	2.86e-05	0.000199	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—TPH2—attention deficit hyperactivity disorder	2.83e-05	0.000197	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.83e-05	0.000197	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	2.8e-05	0.000195	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	2.8e-05	0.000195	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	2.8e-05	0.000195	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	2.78e-05	0.000194	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—DPYD—attention deficit hyperactivity disorder	2.78e-05	0.000194	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	2.77e-05	0.000193	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.76e-05	0.000192	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	2.76e-05	0.000192	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	2.73e-05	0.00019	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	2.71e-05	0.000189	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	2.7e-05	0.000188	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	2.69e-05	0.000187	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	2.68e-05	0.000186	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	2.66e-05	0.000185	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	2.63e-05	0.000183	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	2.6e-05	0.000181	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—CACNA1C—attention deficit hyperactivity disorder	2.59e-05	0.00018	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2.56e-05	0.000178	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	2.52e-05	0.000175	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	2.51e-05	0.000175	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.49e-05	0.000173	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	2.45e-05	0.000171	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	2.45e-05	0.00017	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.41e-05	0.000168	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.33e-05	0.000162	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.33e-05	0.000162	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2.32e-05	0.000161	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—TPH2—attention deficit hyperactivity disorder	2.3e-05	0.00016	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.3e-05	0.00016	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.29e-05	0.000159	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	2.28e-05	0.000158	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.26e-05	0.000157	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—DPYD—attention deficit hyperactivity disorder	2.26e-05	0.000157	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.24e-05	0.000156	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.18e-05	0.000152	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.17e-05	0.000151	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2.16e-05	0.00015	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—ADRA2A—attention deficit hyperactivity disorder	2.15e-05	0.00015	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.14e-05	0.000149	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2.13e-05	0.000148	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.11e-05	0.000147	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.1e-05	0.000146	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—CACNA1C—attention deficit hyperactivity disorder	2.1e-05	0.000146	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.03e-05	0.000142	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.03e-05	0.000142	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.03e-05	0.000141	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2e-05	0.000139	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.96e-05	0.000137	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.96e-05	0.000137	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.96e-05	0.000136	CbGpPWpGaD
Phentolamine—ADRA2B—Hemostasis—EP300—attention deficit hyperactivity disorder	1.94e-05	0.000135	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.93e-05	0.000134	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.93e-05	0.000134	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.9e-05	0.000132	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.89e-05	0.000132	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.89e-05	0.000132	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.89e-05	0.000132	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.86e-05	0.00013	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.84e-05	0.000128	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.83e-05	0.000127	CbGpPWpGaD
Phentolamine—ADRA2C—Hemostasis—EP300—attention deficit hyperactivity disorder	1.81e-05	0.000126	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.8e-05	0.000125	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.8e-05	0.000125	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.78e-05	0.000124	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.78e-05	0.000124	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.77e-05	0.000123	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.77e-05	0.000123	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.76e-05	0.000122	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.75e-05	0.000122	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.72e-05	0.000119	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—COMT—attention deficit hyperactivity disorder	1.71e-05	0.000119	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—MAOA—attention deficit hyperactivity disorder	1.7e-05	0.000118	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.66e-05	0.000115	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.65e-05	0.000115	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.65e-05	0.000115	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.63e-05	0.000113	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.6e-05	0.000111	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.6e-05	0.000111	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.57e-05	0.00011	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.55e-05	0.000108	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.54e-05	0.000107	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.49e-05	0.000104	CbGpPWpGaD
Phentolamine—ADRA2A—Hemostasis—EP300—attention deficit hyperactivity disorder	1.47e-05	0.000102	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.45e-05	0.000101	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.44e-05	0.0001	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—COMT—attention deficit hyperactivity disorder	1.39e-05	9.69e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—MAOA—attention deficit hyperactivity disorder	1.38e-05	9.62e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.38e-05	9.57e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.35e-05	9.36e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.24e-05	8.64e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.16e-05	8.07e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.14e-05	7.94e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.01e-05	7.06e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	9.43e-06	6.56e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—EP300—attention deficit hyperactivity disorder	7.35e-06	5.11e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—EP300—attention deficit hyperactivity disorder	7.29e-06	5.07e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	6.58e-06	4.58e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—EP300—attention deficit hyperactivity disorder	6.15e-06	4.28e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	6.05e-06	4.21e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—EP300—attention deficit hyperactivity disorder	5.97e-06	4.15e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	5.37e-06	3.74e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.99e-06	3.47e-05	CbGpPWpGaD
